HRT use among RRSO patients did not significantly alter postsurgical breast cancer risk (HR 1.35; 95% CI, 0.16 to 11.58), including in BRCA1 mutation carriers [54,55,56,57]. The gene discussed is BRCA1; the disease is breast carcinoma.